Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

RPRX

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

RPRX

AI Research Report

Powered by Claude

Ready to analyze RPRX

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings
NASDAQMarket closed
RPRX
$48.82
$0.39 (+0.81%)
Open
$48.40
Prev close
$48.43
Day range
$48.35 – $49.01
52W range
— – —
Mkt cap
—
P/E
—
EPS
—
Beta
—
  • Finnhub·8h ago

    Royalty Pharma : 2025 Corporate Responsibility Report pdf

    2 02 5 Corporate Responsibility Report A Message from Our Chairman and Chief Executive Officer ...

  • SeekingAlpha·1d ago

    Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside

    Revolution Medicines, Inc. stock jumps 40% on Phase 3 daraxonrasib PDAC data; FDA priority review could mean 2026 approval. Click for this RVMD update.

  • Benzinga·4d ago

    Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $63

    Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $61 to $63.

  • View all news →

Recent insider activity

View all →
  • 4FORM 4
    13d ago
  • 4FORM 4
    15d ago
  • 4FORM 4
    21d ago
  • 4FORM 4
    Mar 4
  • 4FORM 4
    Feb 25